Lavipharm S.A.

LAVI

GRS246003008

Pharmaceuticals

Delayed Athens S.E. Other stock markets 04:57:34 2024-07-05 EDT			5-day change	1st Jan Change
0.875 ^EUR	+0.11%		+3.43%	+9.92%

02-28	Lavipharm S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	Lavipharm S.A. entered into a new asset purchase agreement to acquire Flagyl product line for Greek market from Sanofi.	CI

Lavipharm S A : Announcement 407/2020 (no English translation available)

January 17, 2020 at 11:44 am

Announcement 407/2020 (no English translation available)

Attachments

Original document
Permalink

Disclaimer

Lavipharm SA published this content on 17 January 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 17 January 2020 16:43:02 UTC

Latest news about Lavipharm S.A.

Lavipharm S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	02-28	CI
Lavipharm S.A. entered into a new asset purchase agreement to acquire Flagyl product line for Greek market from Sanofi.	12-10	CI
Lavipharm S.A. signing of an asset purchase agreement to acquire Lonarid N and Lonalgal from Boehringer Ingelheim International GmbH.	11-30	CI
Lavipharm S.A. Reports Earnings Results for the Nine Months Ended September 30, 2023	11-08	CI
Lavipharm S.A. Reports Earnings Results for the Half Year Ended June 30, 2023	23-09-21	CI
Lavipharm S.A.(ATSE:LAVI) added to ATHEX Composite Index	23-06-21	CI
Lavipharm S.A. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-04	CI
Lavipharm S.A. Reports Earnings Results for the Half Year Ended June 30, 2022	22-09-15	CI
Lavipharm S.A. Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-21	CI
Lavipharm S.A. Auditor Raises 'Going Concern' Doubt	22-03-20	CI
Lavipharm S.A. Reports Earnings Results for the Half Year Ended June 30, 2021	21-09-29	CI
Lavipharm S.A. Reports Earnings Results for the Full Year Ended December 31, 2020	21-04-26	CI
Lavipharm S.A. Auditor Raises 'Going Concern' Doubt	21-04-25	CI
Zentiva Reinforces Its Presence in Greece by Signing A Partnership with the Company Lavipharm S.A	20-10-19	CI
Lavipharm S.A. Auditor Raises 'Going Concern' Doubt	20-05-07	CI
Lavipharm S.A. Auditor Raises 'Going Concern' Doubt	19-04-24	CI
Lavipharm S.A. Auditor Raises 'Going Concern' Doubt	18-04-26	CI
Lavipharm Announces Consolidated Earnings Results for the First Half of 2015	15-09-21	CI
Robertet SA and Codif Recherche & Nature acquired Hitex S.A. from Lavipharm S.A. for €3.1 million.	13-12-31	CI
Lavipharm S.A. Announces Earnings Results for the Year Ended December 31, 2011	12-09-25	CI
Lavipharm S.A. Reports Consolidated and Parent Earnings Results for the Second Quarter and Six Months Ended June 30, 2012	12-08-29	CI
Lavipharm SA Reports Consolidated and Company Earnings Results for the First Quarter Ended March 31, 2012	12-05-29	CI

Chart Lavipharm S.A.

Duration

Period

More charts

Company Profile

Lavipharm SA is a Greek commercial and industrial enterprise engaged in the development, manufacture, marketing and distribution of pharmaceutical, cosmetic and over-the-counter (OTC) products. Its main pharmaceutical products cover such categories as anti-inflammatory, asthma controlling, neurological, antiseptic, analgesic, dermatological and gastrointestinal therapies. Its cosmetic products are offered under the brand names of Castalia Soins Dermocosmetiques and Laviderm Active Technology and are used for skin, face and body care, as well as for scalp and hair problems. Its OTC products include cold and flu remedies, oral care, dermatological products, condoms, antiseptics, analgesics, laxatives and gynecology products. It is the parent company of Lavipharm Group of Companies. In January 2014, Robertet SA acquired together with CODIF the HITEX company, specialized in subcontracting of carbon dioxide extraction, from Lavipharm SA.

Sector

Pharmaceuticals

More about the company

Income Statement Evolution

More financial data

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
LAVIPHARM S.A.	+9.92%	159M
SUN PHARMACEUTICAL INDUSTRIES LTD.	+24.39%	44.76B
OTSUKA HOLDINGS CO., LTD.	+30.99%	23.16B
SANDOZ GROUP AG	+24.02%	16.02B
CIPLA LIMITED	+20.61%	14.32B
ZYDUS LIFESCIENCES LIMITED	+68.74%	13.7B
THE MEDICINES COMPANY	-0.05%	6.79B
ONO PHARMACEUTICAL CO., LTD.	-13.29%	6.47B
STADA ARZNEIMITTEL	-8.87%	5.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+14.00%	5.65B